Brought to you by 
Astellas collaborates with Proteostasis on UPR candidates in possible $1.2bn deal
02 Feb 2023
Executive Summary
Proteostasis Therapeutics Inc. (mostly focused on orphan and neurodegenerative diseases caused by defects in protein folding, trafficking, and clearance) and Astellas Pharma Inc. will research and develop therapeutic candidates that modulate the unfolded protein response (UPR) pathway.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Genomics-Proteomics
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas collaborates with Proteostasis on UPR candidates in possible $1.2bn deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice